嘉应制药
(002198)
| 流通市值：35.22亿 | | | 总市值：35.22亿 |
| 流通股本：5.08亿 | | | 总股本：5.08亿 |
| 报告期 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 257,414,670.58 | 128,497,088.51 | 659,195,732.41 | 414,613,931.27 |
| 营业收入 | 257,414,670.58 | 128,497,088.51 | 659,195,732.41 | 414,613,931.27 |
| 二、营业总成本 | 237,643,784.51 | 115,949,772.87 | 603,781,284.66 | 386,187,135.3 |
| 营业成本 | 85,687,599.52 | 44,407,735.68 | 228,528,333.08 | 127,015,204.62 |
| 税金及附加 | 4,387,019.18 | 2,104,227.81 | 10,585,955.07 | 7,330,865.15 |
| 销售费用 | 123,519,809.85 | 58,301,382.66 | 307,439,495.33 | 213,808,708.31 |
| 管理费用 | 21,573,876.69 | 9,966,922.65 | 43,733,214.35 | 33,399,846.91 |
| 研发费用 | 3,451,304.73 | 1,657,099.81 | 15,340,066.16 | 7,089,552.01 |
| 财务费用 | -975,825.46 | -487,595.74 | -1,845,779.33 | -2,457,041.7 |
| 其中:利息费用 | - | - | 454,167.84 | 454,167.84 |
| 其中:利息收入 | 985,464.32 | 502,615.94 | 2,336,699.25 | 2,940,905.95 |
| 加:公允价值变动收益 | - | - | 260,821.92 | - |
| 加:投资收益 | 146,764.25 | -813,366.3 | 405,321.53 | -557,838.13 |
| 资产处置收益 | - | - | -10,280.4 | -10,280.4 |
| 资产减值损失(新) | -435,980.55 | - | -689,936.01 | - |
| 信用减值损失(新) | 563,820.1 | - | -2,629,488.6 | -395,103.19 |
| 其他收益 | 1,419,014.3 | 1,386,076.13 | 1,133,456.97 | 125,653.86 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 21,464,504.17 | 13,120,025.47 | 53,884,343.16 | 27,589,228.11 |
| 加:营业外收入 | 65,612.85 | 45,881.54 | 199,779.89 | 12,809.26 |
| 减:营业外支出 | 665,686.33 | 3,422.1 | 2,986,655.21 | 452,024.72 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 20,864,430.69 | 13,162,484.91 | 51,097,467.84 | 27,150,012.65 |
| 减:所得税费用 | 2,615,889.34 | 976,515.86 | 7,162,764.12 | 4,890,720.05 |
| 六、净利润 | 18,248,541.35 | 12,185,969.05 | 43,934,703.72 | 22,259,292.6 |
| 持续经营净利润 | 18,248,541.35 | 12,185,969.05 | 43,934,703.72 | - |
| 归属于母公司股东的净利润 | 18,248,541.35 | 12,185,969.05 | 43,934,703.72 | 22,259,292.6 |
| (一)基本每股收益 | 0.04 | 0.02 | 0.09 | 0.04 |
| (二)稀释每股收益 | 0.04 | 0.02 | 0.09 | 0.04 |
| 九、综合收益总额 | 18,248,541.35 | 12,185,969.05 | 43,934,703.72 | 22,259,292.6 |
| 归属于母公司股东的综合收益总额 | 18,248,541.35 | 12,185,969.05 | 43,934,703.72 | 22,259,292.6 |
| 公告日期 | 2023-08-26 | 2023-04-29 | 2023-04-29 | 2022-10-28 |
| 审计意见(境内) | | | 标准无保留意见 | |